Drug Profile
Human papillomavirus vaccine - ARTES/BioSun Pharmed
Latest Information Update: 25 Oct 2021
Price :
$50
*
At a glance
- Originator ARTES Biotechnology
- Developer ARTES Biotechnology; BioSun Pharmed
- Class Cancer vaccines; Papillomavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Human papillomavirus infections
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for research development in Human-papillomavirus-infections(Prevention) in Iran (Parenteral)
- 04 Nov 2016 ARTES and BioSun agree to co-develop human papillomavirus (HPV) vaccine in Iran for Human papillomavirus infections
- 04 Nov 2016 Early research in Human papillomavirus infections (Prevention) in Iran (Parenteral)